RELATING TO ACCESS TO TREATMENT FOR TERMINALLY ILL PATIENTS.
Summary
Beginning on January 1, 2024, permits manufacturers of investigational drugs or biological products to make these drugs and products available to terminally ill patients under certain conditions.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jan 2023
Committee Review
Floor Vote
Governor
Introduced Jan 23, 2023
Last action Jan 30, 2023
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
1
Jan 30, 2023
Committee
Referred to HLT, CPC, FIN, referral sheet 3
lower
Jan 25, 2023
Introduced
Introduced and Pass First Reading.
lower
Jan 23, 2023
Introduced
Pending introduction.
lower
15 primary · 1 co-sponsor
Sponsors
Role
Legislator
Party
State
District
P
Amy Perruso
DDemocratic
P
Cedric Gates
DDemocratic
P
Chris Todd
DDemocratic
P
David Tarnas
DDemocratic
P
Della Belatti
DDemocratic
P
Jenna Takenouchi
DDemocratic
P
Lisa Marten
DDemocratic
P
Mark Nakashima
DDemocratic
P
May Mizuno
DDemocratic
P
Natalia Hussey-Burdick
DDemocratic
P
Rachele Lamosao
DDemocratic
P
Scot Matayoshi
DDemocratic
P
Scott Nishimoto
DDemocratic
P
Sonny Ganaden
DDemocratic
P
Terez Amato
DDemocratic
Co
Mahina Poepoe
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HB 966
Scope: HI
Hi! I can help you understand HB 966. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline